Bacteriuria Eradication Through Probiotics (BERP)
Primary Purpose
Bacteriuria
Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1
Sponsored by
About this trial
This is an interventional treatment trial for Bacteriuria focused on measuring bacteriuria, urinary tract infection, probiotics, lactobacillus, vagina, bladder, neurogenic bladder, spina bifida, myelomeningocele, neuropathic bladder
Eligibility Criteria
Inclusion Criteria:
- Eligible subjects are girls (age 3 months to 18 years) with spina bifida as a sole urologic diagnosis
- perform clean intermittent catheterization because of neurogenic bladder.
- Secondary vesicoureteral reflux is permissible.
- Patients with appendicovesicostomies and no other forms of urinary diversion are permitted.
Exclusion Criteria:
- Patients will be excluded if they are taking antibiotics
- immunosuppressed, i.e., transplant recipients or children with congenital immunodeficiencies
- poorly controlled diabetes
- untreated HIV infection
- immunosuppression from corticosteroids
- malnutrition
- pregnancy
- chronic indwelling catheters in the bladder
- any urinary diversion or bladder augmentation.
Sites / Locations
- Texas Children's Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
Oral probiotics
Outcomes
Primary Outcome Measures
bacteriuria
Secondary Outcome Measures
urinary tract infections
Full Information
NCT ID
NCT00717600
First Posted
July 16, 2008
Last Updated
July 16, 2008
Sponsor
Baylor College of Medicine
Collaborators
Chr Hansen, Lawson Health Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT00717600
Brief Title
Bacteriuria Eradication Through Probiotics
Acronym
BERP
Official Title
Bacteriuria Eradication Through Probiotics
Study Type
Interventional
2. Study Status
Record Verification Date
July 2008
Overall Recruitment Status
Unknown status
Study Start Date
January 2008 (undefined)
Primary Completion Date
September 2008 (Anticipated)
Study Completion Date
September 2008 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Baylor College of Medicine
Collaborators
Chr Hansen, Lawson Health Research Institute
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Many children who catheterize their bladders because of spina bifida or other neurologic disorders have bacteriuria. This can lead to urinary tract infections by bacteria from the gut which colonize the vagina and are carried into the bladder during catheter passage. We seek to test whether oral administration of probiotic bacteria can "displace" these vagina-derived uropathogens and reduce or prevent bacteriuria in girls with spina bifida who empty their bladders through catheterization.
Detailed Description
In children with spina bifida and neurogenic bladder dysfunction, the need for intermittent bladder catheterization increases the risk of bacteriuria. In many patients, this leads to a clinically significant urinary tract infection (UTI). Many of these children are placed on long term, low dose antibiotic suppression to prevent recurrent urinary infection. Unfortunately, bacteriuria often persists despite daily antibiotic therapy, and breakthrough urinary tract infections are common. Furthermore, this approach carries the potential for deleterious side effects, and may promote the development of antibiotic-resistant bacteria.
Urinary tract infection in girls occurs when virulent bacteria migrate from the rectum and colonize the vagina and peri-urethral mucosa, thus gaining access to the bladder. In girls with spina bifida, access to the bladder is greatly facilitated by catheter passage. Antibiotic prophylaxis relies on maintaining a low dose of antibiotic in the urinary stream, which decreases peri-urethral colonization, and prevents proliferation of bacteria after they gain access to the bladder. An alternative approach to daily antibiotic prophylaxis is to decrease the risk of urinary colonization with virulent bacteria by supplementing the normal bacteria flora with non-infection causing strains of bacteria.
Probiotics are dietary supplements containing potentially beneficial bacterial strains such as Lactobacillus. The safety of oral administration of probiotics has been demonstrated in several studies over the last 30 years. Studies using L. rhamnosus GG, a probiotic introduced in the late 1980s to alleviate diarrhea, have shown promising results when used for UTI prevention. In one study, researchers found that the subjects consuming Lactobacillus GG drinks had fewer episodes of UTI compared to those women not receiving probiotics. A placebo-controlled study in premature infants also used L. rhamnosus GG in an attempt to prevent UTI. The number of urinary infections was reduced but statistically the difference was not significant. Finally, a recent randomized clinical trial demonstrated that the rate of UTI in patients taking prophylactic antibiotics was similar to that of patients taking Lactobacillus acidophilus alone. The efficacy of probiotic usage in the spina bifida population has not been reported.
Our objective is to determine whether over the course of 3 months, probiotics can reduce preexisting or new bacteriuria in girls with spina bifida who perform clean intermittent catheterization for bladder emptying. We will also attempt to ascertain whether changes in bacteriuria are associated with vaginal colonization by the administered probiotics.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bacteriuria
Keywords
bacteriuria, urinary tract infection, probiotics, lactobacillus, vagina, bladder, neurogenic bladder, spina bifida, myelomeningocele, neuropathic bladder
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Oral probiotics
Intervention Type
Dietary Supplement
Intervention Name(s)
Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1
Other Intervention Name(s)
Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 (Urex cap-5 from CHR. Hansen), batch 2750558
Intervention Description
2x10^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
Primary Outcome Measure Information:
Title
bacteriuria
Time Frame
3 months
Secondary Outcome Measure Information:
Title
urinary tract infections
Time Frame
3 months
10. Eligibility
Sex
Female
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Eligible subjects are girls (age 3 months to 18 years) with spina bifida as a sole urologic diagnosis
perform clean intermittent catheterization because of neurogenic bladder.
Secondary vesicoureteral reflux is permissible.
Patients with appendicovesicostomies and no other forms of urinary diversion are permitted.
Exclusion Criteria:
Patients will be excluded if they are taking antibiotics
immunosuppressed, i.e., transplant recipients or children with congenital immunodeficiencies
poorly controlled diabetes
untreated HIV infection
immunosuppression from corticosteroids
malnutrition
pregnancy
chronic indwelling catheters in the bladder
any urinary diversion or bladder augmentation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric A Jones, M.D.
Organizational Affiliation
Texas Children's Hospital, Baylor College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Texas Children's Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Bacteriuria Eradication Through Probiotics
We'll reach out to this number within 24 hrs